Join Now - it is FREE

Basic level includes our interactive biotech chatroom, forum, biotech stock screener; you also receive the biotech digest in your email everyday.

Celsion Corporation ($CLSN) stock soared in pre-market trading session as the company announced withdrawing its plan of a stock offering. The company had originally filed on April 5 an S-1 statement with the Securities and Exchange Commission for the sale of shares. The company later, amended the application for the sale of 2.45 million common shares and pre-funded and base warrants to buy over 4 million shares. The company has now stated that it “does not intend to pursue the contemplated offering at this time." Celsion had earlier announced regaining the minimum-bid compliance for the continued listing of its stock on the Nasdaq.
Celsion stock gained over 88 percent in the pre-market trading session, trimming its 12 months loss to 89 percent. It is down 51 percent on YTD basis.

HTG Molecular Diagnostics Inc. ($HTGM) stock has shown strong movement as the company announced inking a new Statement of Work (SOW) with Qiagen NV. The contract has been signed with a subsidiary of the company. It pertains to the initial phase of a multi-stage project to develop a next-generation sequencing-based companion diagnostic assay for an unnamed pharmaceutical firm. Under the terms of the agreement, Qiagen will pay HTG Molecular  low single-digit millions for the initial work performed under the SOW . The net profits generated in the initial phase will be shared by both the companies.
HTG Molecular Diagnostics Inc. stock has gained 4 percent in the past twelve months while its Year to Date growth stands at 39 percent.

 

Adamis Pharmaceuticals ($ADMP) announced receiving the FDA approval for its epinephrine auto-injector. The product will compete with Mylan’s EpiPen and will be marketed under the brand name Symjepi.

Selecta Biosciences ($SELB) announced positive results from a Phase 2 clinical trial evaluating lead product candidate SEL-212 for treating patients suffering from chronic severe gout. Within one month of treatment, 15% of patients receiving SEL-212 experienced a gout flare (compared to 50% of patients treated with pegsiticase alone.

Lannett Company ($LCI) announced receiving the FDA approval for its Abbreviated New Drug Application (ANDA) for Amantadine Hydrochloride Capsules USP, 100 mg, the therapeutic equivalent to the reference standard drug of Sandoz Pharmaceuticals.  Amantadine hydrochloride capsules are indicated for the treatment of parkinsonism.

Novartis ($NVS) announced the FDA accepting its Abbreviated New Drug Application (ANDA) seeking approval of a generic version of GlaxoSmithKline's asthma/COPD med Advair Diskus. The drug is being developed by the Sandoz unit of the group.

 
Bristol Myers Squibb ($BMY) announced inking a new agreement to sell its Swords, Ireland manufacturing site to Seoul, South Korea-based SK Biotek Co., Ltd. The financial terms of the deal have not been disclosed. The companies expect the transaction to be finalized in the fourth quarter.
Immune Pharmaceuticals ($IMNP) announced signing a new deal with Mylan for the repurchase of Ceplene (histamine dihydrochloride) assets that it sold to it in 2012.  The deal provides for the payment of cash fee, payable in installments, and milestones to Mylan.

Brokerage
Action
Company
Rating
Price Target
Impact on Share Price
Jefferies Group LLC
Reiterates
Abbott Laboratories (ABT)
Buy
$55.00
Low
Cantor Fitzgerald
Initiates
Aclaris Therapeutics (ACRS)
Overweight

High
Cantor Fitzgerald
Initiates
Allergan PLC. (AGN)
Neutral

Low
Leerink Swann
Upgrades
Celgene Corporation (CELG)
Market Perform -> Outperform

High
Cantor Fitzgerald
Initiates
Endo International PLC (ENDP)
Neutral

Low
J P Morgan Chase & Co
Reiterates
GlaxoSmithKline PLC (GSK)
Neutral

Low
Cantor Fitzgerald
Initiates
Horizon Pharma PLC (HZNP)
Overweight

High
Jefferies Group LLC
Reiterates
INC Research Holdings (INCR)
Buy
$62.00
Low

Gainers (% price change) Last Trade Change Mkt Cap
Antares Pharma Inc ATRS 2.98 +0.12 (4.20%) 447.45M
BioScrip Inc BIOS 2.52 +0.09 (3.70%) 304.88M
Simulations Plus, Inc. SLP 12.10 +0.40 (3.42%) 209.51M
Fonar Corporation FONR 28.25 +0.90 (3.29%) 183.34M
Spectranetics Corp SPNC 29.95 +0.80 (2.74%) 1.37B
Losers (% price change)
Keryx Biopharmaceuticals KERX 6.06 -0.53 (-8.04%) 655.32M
AMAG Pharmaceuticals, Inc AMAG 16.10 -1.25 (-7.20%) 565.86M
Clovis Oncology Inc CLVS 59.70 -3.61 (-5.70%) 2.69B
Horizon Pharma PLC HZNP 10.20 -0.55 (-5.12%) 1.66B
BioCryst Pharmaceuticals BCRX 5.53 -0.27 (-4.66%) 470.70M
Most Actives (dollar volume)
Alexion Pharmaceuticals ALXN 117.98 -0.02 (-0.02%) 28.95B
Johnson & Johnson JNJ 133.04 +0.27 (0.20%) 360.42B
Pfizer Inc. PFE 32.81 +0.12 (0.37%) 196.05B
Amgen, Inc. AMGN 164.11 -0.99 (-0.60%) 121.18B
UnitedHealth Group Inc UNH 180.38 -1.23 (-0.68%) 175.08B